Back to top
more

Organon & Co. (OGN)

(Delayed Data from NYSE)

$20.29 USD

20.29
1,280,276

+0.13 (0.64%)

Updated Sep 12, 2024 04:00 PM ET

After-Market: $20.31 +0.02 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (180 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

Smart Beta ETF report for SPYD

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

Smart Beta ETF report for RYH

Organon (OGN) Q1 Earnings and Revenues Beat Estimates

Organon (OGN) delivered earnings and revenue surprises of 25.95% and 3.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should WisdomTree U.S. MidCap ETF (EZM) Be on Your Investing Radar?

Style Box ETF report for EZM

Why Organon (OGN) is Poised to Beat Earnings Estimates Again

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is WisdomTree U.S. MidCap ETF (EZM) a Strong ETF Right Now?

Smart Beta ETF report for EZM

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report?

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Why Organon (OGN) Could Beat Earnings Estimates Again

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Is SPDRSP PHARMA (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Organon's (OGN) Earnings & Revenues Surpass Estimates in Q3

Organon's (OGN) earnings and revenues trump estimates in the third quarter of 2021. Shares down in pre-market trading.

Organon (OGN) to Report Q3 Earnings: What's in the Cards?

Organon (OGN) is set to provide updates on its earnings and revenues when it reports third-quarter 2021 results.

Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates

Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.

Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips

Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.